TNF receptor-associated factor 1 (TRAF1)

TNF receptor-associated factor 1 (TRAF1) is a critical cytoplasmic adapter protein and signal transducer that mediates signaling for the tumor necrosis factor receptor (TNFR) superfamily [1, 2]. Unlike most other TRAF family members, TRAF1 lacks a RING finger domain and functions primarily as a scaffolding protein, forming heterotrimers with TRAF2 to recruit cellular inhibitors of apoptosis (cIAPs) and activate the canonical and non-canonical NF-kappaB and JNK pathways [2, 6, 7]. It plays a sophisticated dual role in human health; while it promotes pro-survival signaling in activated lymphocytes and contributes to the pathogenesis of B-cell malignancies like chronic lymphocytic leukemia, it also serves as a negative regulator of Toll-like receptor (TLR) and Nod-like receptor (NLR) signaling by sequestering the linear ubiquitin assembly complex (LUBAC) [1, 5, 10]. In clinical contexts, TRAF1 is a major focus for autoimmune research, as genetic polymorphisms in the TRAF1-C5 locus are strongly linked to the risk and severity of rheumatoid arthritis and systemic lupus erythematosus [5, 9]. Elevated expression of TRAF1 is frequently observed in various cancers, including non-small cell lung cancer and lymphoma, where it facilitates apoptotic resistance and tumor growth [9, 16, 20]. Although there are currently no approved drugs that target TRAF1 directly, its signaling axis is modulated by widely used anti-TNF biologics such as adalimumab and etanercept. Recent drug development efforts are exploring the inhibition of its upstream regulators, such as PKN1, and the disruption of specific protein-protein interactions (e.g., the TRAF1/cIAP2 complex) to treat chronic inflammatory conditions and cancer [6, 12, 14].

Other names

EBI6Epstein-Barr virus-induced protein 6MGC:10353

Modulation of NF-kappaB and JNK signaling pathways by acting as a scaffolding protein that recruits TRAF2 and cellular inhibitors of apoptosis (cIAPs) to the TNF receptor complex. It also acts as a negative regulator of Toll-like receptor signaling by sequestering the linear ubiquitin assembly complex (LUBAC) [1, 5, 10]. Drugs targeting this pathway typically inhibit the interaction between TNF receptors and their ligands or modulate the stability and recruitment of the TRAF1 complex [6, 12, 14].